Fulminant hepatitis-A in a child using sodium valproate therapy: Case report
Küçük Resim Yok
Tarih
2010
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
The risk of fulminant liver failure due to hepatitis A infection increases in the patients with underlying chronic liver diseases and hepatotoxic drug-use. In this case report, we aimed to emphasize the development of fulminant liver failure due to hepatitis A infection and importance of hepatitis A vaccination in these cases. A five-year age boy who treated with sodium valproate for three years was admitted with the symptoms of fulminant liver failure and encephalopathy to our emergency clinic. Hepatitis A IgM-antibody was found positive and serum sodium valproate level was mildly elevated. In conclusion, fulminant progression risk due to hepatitis-A infection increase in the patients using hepatotoxic drug such as sodium valproate. Therefore, hepatitis-A vaccination for these cases is important for decreasing the risk of fulminant hepatitis. Copyright © 2010 by Türkiye Klinikleri.
Açıklama
Anahtar Kelimeler
Child; Hepatic Encephalopathy; Hepatitis A; Hepatitis A Vaccines; Liver Failure, Acute; Valproic Acid, Alanine Aminotransferase; Aspartate Aminotransferase; Carnitine; Flumazenil; Hepatitis A Antibody; Hepatitis A Vaccine; Immunoglobulin M Antibody; Lactulose; Levodopa; Penicillin G; Ranitidine; Valproic Acid; Vitamin K Group; Antibody Titer; Article; Case Report; Child; Drug Blood Level; Electroencephalogram; Emergency Ward; Febrile Convulsion; Hepatic Encephalopathy; Hepatitis A; Human; Liver Failure; Male; Preschool Child
Kaynak
Turkiye Klinikleri Pediatri
WoS Q Değeri
Scopus Q Değeri
Q4
Cilt
19
Sayı
2
